FR0004056851 - Common Stock

We assign a fundamental rating of **2** out of 10 to **VLA**. **VLA** was compared to 81 industry peers in the **Biotechnology** industry. Both the profitability and financial health of **VLA** have multiple concerns. **VLA** is valied quite expensively at the moment, while it does show a decent growth rate.

In the past 5 years **VLA** always reported negative net income.

In multiple years **VLA** reported negative operating cash flow during the last 5 years.

With a **Return On Equity** value of **-119.91%**, **VLA** is not doing good in the industry: **64.47%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -33.43% | ||

ROE | -119.91% | ||

ROIC | N/A |

ROA(3y)-18.03%

ROA(5y)-13.82%

ROE(3y)-62.44%

ROE(5y)-54.36%

ROIC(3y)N/A

ROIC(5y)N/A

With a **Gross Margin** value of **36.83%**, **VLA** perfoms like the industry average, outperforming **55.26%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **VLA** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 36.83% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-15.75%

GM growth 5Y-10.74%

Compared to 5 years ago, **VLA** has more shares outstanding

Compared to 1 year ago, **VLA** has a worse debt to assets ratio.

Based on the Altman-Z score of **-1.17**, we must say that **VLA** is in the distress zone and has some risk of bankruptcy.

A Debt/Equity ratio of **1.26** is on the high side and indicates that **VLA** has dependencies on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.26 | ||

Debt/FCF | N/A | ||

Altman-Z | -1.17 |

ROIC/WACCN/A

WACC6.85%

A Quick Ratio of **1.37** indicates that **VLA** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.65 | ||

Quick Ratio | 1.37 |

The **Revenue** has been growing slightly by **6.34%** on average over the past years.

EPS 1Y (TTM)83.19%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%415.38%

Revenue 1Y (TTM)-59.29%

Revenue growth 3Y11.69%

Revenue growth 5Y6.34%

Sales Q2Q%-2.25%

The **Earnings Per Share** is expected to grow by **35.16%** on average over the next years. This is a very strong growth

EPS Next Y119.02%

EPS Next 2Y25.23%

EPS Next 3Y20.92%

EPS Next 5Y35.16%

Revenue Next Year22.09%

Revenue Next 2Y13.56%

Revenue Next 3Y18.18%

Revenue Next 5Y22.69%

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **VLA**. No positive earnings are expected for the next year.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.23%

EPS Next 3Y20.92%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**VALNEVA SE**

EPA:VLA (6/14/2024, 7:00:00 PM)

**3.28**

**-0.19 (-5.53%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap228.21M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -33.43% | ||

ROE | -119.91% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 36.83% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.49

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1.26 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.65 | ||

Quick Ratio | 1.37 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)83.19%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y119.02%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-59.29%

Revenue growth 3Y11.69%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y